Skip to Main Content

hero-news

News

Category: Latest Updates

Volastra Therapeutics In-Licenses Clinical Stage KIF18A Inhibitor and Secures $60 Million in Series A Funding to Further Advance Cancer-Focused Pipeline

Financing led by founding investors Polaris Partners and ARCH Venture Partners alongside Lilly. Funding will...

Volastra Therapeutics Named One of Fierce Biotech’s “Fierce 15” Companies of 2022

September 12, 2022

NEW YORK, September 12, 2022 – Volastra Therapeutics, an oncology company focused on exploiting chromosomal...

Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program Targeting Chromosomally Unstable Tumors at FASEB Aneuploidy Conference

September 9, 2022

Treatment with KIF18A inhibitor led to substantial, dose-dependent inhibition of tumor growth in multiple tumor...

Volastra Therapeutics Announces Participation in 2022 Guggenheim Synthetic Lethality Day

NEW YORK, May 12, 2022 – Volastra Therapeutics, an oncology company focused on exploiting chromosomal...

Volastra Therapeutics Announces Drug Discovery Collaboration with Bristol Myers Squibb

Bristol Myers Squibb to leverage Volastra’s proprietary CINtech platform to discover and develop oncology drug...